bevacizumab
roche
['gyn', 'beva', 'bevacizumab', '5553']
2/2 #gyncsm ab 5553 #asco22 suggests that bev is mainly effective in patients w/ poorly chemosensitive diseases. highest benefit from bevacizumab in pfs and os were high-risk diseases (stage iv, or incompletely resected stage iii poor kelim score
#ovca survivor; research advocate; author; co-moderator #gyncsm chat;  #ASCO22 Feature Voice  COI: https://t.co/AUF1EprNVt Opinions are my own.